Healthcare

News: Recro Pharma Offering closed $REPH

Recro Pharma, Inc., a revenue generating specialty pharmaceutical company,  has announced the closing of private placement announced on July 1, 2015. Pursuant to the securities purchase agreement with a group of institutional accredited investors led by Broadfin Capital, LLC, the Company issued 1,379,311 shares of common stock, providing the Company with gross proceeds of approximately $16

News: Recro Pharma Offering closed $REPH Read More »

News: FDA Approves Generic Focalin XR $IPCI

Intellipharmaceutics International Inc., a pharmaceutical company specializing in the research, development and manufacture of novel and generic controlled-release and targeted-release oral solid dosage drugs, today advised that the United States Food and Drug Administration (“FDA”) has indicated to the Company that it has rescinded its previous requirement that the Company meet newly-imposed conditions for bioequivalence

News: FDA Approves Generic Focalin XR $IPCI Read More »